Financial Report: Amgen

Amgen

3Q Revenues: $5.8 billion (+2%)

3Q Earnings: $2.0 billion (+8%)

YTD Revenues: $17.0 billion (+6%)

YTD Earnings: $5.8 billion (+13%)

Comments: Enbrel sales were flat at $1.5 billion impacted by competition and unfavorable changes in inventory levels. Neulasta sales decreased 5% to $1.2 billion due to lower unit demand. Aranesp sales were up 8% to $531 million driven by a shift by some U.S. dialysis customers from EPOGEN to Aranesp. Sensipar/Mimpara sales increased 18% to $415 million driven by net selling price and higher unit demand. XGEVA sales were up 4% to $394 million, and Prolia sales increased 18% to $379 million driven by higher unit demand.EPOGEN sales were down 31% to $335 million impacted by competition and a shift by some U.S. dialysis customers to Aranesp. KYPROLIS sales were up 34% to $183 million driven by higher unit demand. NEUPOGEN sales dropped 36% to $183 million impacted by competition in the U.S. Vectibix sales were up 24% to $164 million driven by higher unit demand. Nplate sales were up 10% to $151 million.